Abstract
Recent advances in cancer molecular biology have resulted in parallel and unprecedented progress in the development of targeted cancer therapy. Targeted therapy can provide higher efficacy and lower toxicity than conventional chemotherapy for cancer. However, like traditional chemotherapy, molecularly targeted cancer therapy also faces the challenge of drug resistance. Multiple mechanisms are responsible for chemotherapy resistance in tumors, including over-expression of efflux transporters, somatic alterations of drug targets, deregulation of apoptosis, and numerous pharmacokinetic issues. Nanotechnology based approaches are proving to be efficacious in overcoming drug resistance in cancer. Combination of targeted therapies with nanotechnology approaches is a promising strategy to overcome targeted therapy drug resistance in cancer treatment. This review discusses the mechanisms of targeted drug resistance in cancer and discusses nanotechnology approaches to circumvent this resistance.
Keywords: Drug resistance, nanotechnology, targeted cancer therapy.
Current Medicinal Chemistry
Title:Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
Volume: 22 Issue: 11
Author(s): Yan Gao, Jacson K. Shen, Lara Milane, Francis J. Hornicek, Mansoor M. Amiji and Zhenfeng Duan
Affiliation:
Keywords: Drug resistance, nanotechnology, targeted cancer therapy.
Abstract: Recent advances in cancer molecular biology have resulted in parallel and unprecedented progress in the development of targeted cancer therapy. Targeted therapy can provide higher efficacy and lower toxicity than conventional chemotherapy for cancer. However, like traditional chemotherapy, molecularly targeted cancer therapy also faces the challenge of drug resistance. Multiple mechanisms are responsible for chemotherapy resistance in tumors, including over-expression of efflux transporters, somatic alterations of drug targets, deregulation of apoptosis, and numerous pharmacokinetic issues. Nanotechnology based approaches are proving to be efficacious in overcoming drug resistance in cancer. Combination of targeted therapies with nanotechnology approaches is a promising strategy to overcome targeted therapy drug resistance in cancer treatment. This review discusses the mechanisms of targeted drug resistance in cancer and discusses nanotechnology approaches to circumvent this resistance.
Export Options
About this article
Cite this article as:
Gao Yan, Shen K. Jacson, Milane Lara, Hornicek J. Francis, Amiji M. Mansoor and Duan Zhenfeng, Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance, Current Medicinal Chemistry 2015; 22(11) . https://dx.doi.org/10.2174/0929867322666150209151851
| DOI https://dx.doi.org/10.2174/0929867322666150209151851 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Mitochondrial Diseases in Childhood
Current Molecular Medicine Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery The Role of Transforming Growth Factor-β in Cardiac Fibrosis
Current Enzyme Inhibition Editorial (Thematic Issue Title: Myocardial Cell Death: Molecular Mechanisms & Drug Targets)
Cardiovascular & Hematological Agents in Medicinal Chemistry The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Therapy Against Ischemic Injury
Current Pharmaceutical Design Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy
Medicinal Chemistry Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Exercise-induced Physiological Hypertrophy: Insights from Genomics
Current Genomics Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Amniotic Fluid Embolism: Moving Diagnosis Through the Time. From the Mechanical Pulmonary Vascular Occlusion Until An Immuno - Inflammatory Pathogenesis?
Current Pharmaceutical Biotechnology

